Study S002762

Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07668401
Acronym: AMAZE 13
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 400
Start: 2027-01-07
Primary completion: 2029-01-11
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight
Interventions: DRUG:Zenagamtide; DRUG:Placebo ( matched to Zenagamtide)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1335-9475

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to week 80]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.